The Chronic Cough drugs in development market research report provides comprehensive information on the therapeutics under development for Chronic Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chronic Cough. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Chronic Cough - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chronic Cough and features dormant and discontinued products.

GlobalData tracks 27 drugs in development for Chronic Cough by 24 companies/universities/institutes. The top development phase for Chronic Cough is phase ii with ten drugs in that stage. The Chronic Cough pipeline has 27 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Chronic Cough pipeline products market are: Nocion Therapeutics, Createrna Science and Technology and Exxel Pharma.

The key targets in the Chronic Cough pipeline products market include P2X Purinoceptor 3 (P2RX3) , Sodium Channel, and Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99).

The key mechanisms of action in the Chronic Cough pipeline product include P2X Purinoceptor 3 (P2RX3) Antagonist with ten drugs in Pre-Registration. The Chronic Cough pipeline products include four routes of administration with the top ROA being Oral and three key molecule types in the Chronic Cough pipeline products market including Small Molecule, and Monoclonal Antibody.

Chronic Cough overview

Chronic cough is a respiratory disorder, characterized by a persistent cough lasting at least eight weeks or longer. Coughing is a natural defense mechanism, clearing bronchial secretions and eliminating inhaled foreign particles. Chronic cough can result from various causes, including respiratory infections like bronchitis or pneumonia, gastroesophageal reflux disease (GERD), asthma, and postnasal drip. Understanding and addressing the underlying condition is essential in managing chronic cough effectively.

For a complete picture of Chronic Cough’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.